You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Aberration-correcting Topologically Optimized Metasurface (ATOM)

    SBC: PHYSICAL SCIENCES INC.            Topic: HR001119S003524

    Metalenses, with their ability to arbitrarily control the amplitude and phase of light across a band of wavelengths, have the potential to disrupt imaging and communication systems which rely on traditional lenses to focus, collimate, and otherwise manipulate optical signals, and are under increasing pressure to operate with reduced size and weight. We propose to design, develop, and demonstrate a ...

    STTR Phase I 2020 Department of DefenseDefense Advanced Research Projects Agency
  2. Advanced Tracking Techniques for FOPEN GMTI Radars

    SBC: ALPHATECH, INC.            Topic: N/A

    The utility of continuously tracking vehicles in a battlefield has been demonstrated during the Gulf War and other recent conflicts. However, the ability to achieve reliable continuous tracking in many environments will require the use of FOPEN radar andefficient use of sensor resources. In this effort we extend current research to include heterogeneous terrain and apply this model to simulations. ...

    STTR Phase I 2001 Department of DefenseDefense Advanced Research Projects Agency
  3. Aerosolized hyaluronic acid as a treatment for emphysema

    SBC: EXHALE THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease afflicts 12-14 million people in the US and in an advanced form, emphysema, disables 2 million and ultimately leads to death. No approved, existing treatment can arrest emphysema's progressive destruction of the lung. Exhale Therapeutics, Inc intends to develop and commercialize aeros ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  4. A Genes-to-Molecules Platform for Expanding Natural Product Diversity

    SBC: Lassogen, Inc.            Topic: NCCIH

    Project Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. AIRWAY PERFUSION ASSISTED LIQUID VENTILATOR

    SBC: MALLARD MEDICAL CO., INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We have developed and patented (U.S. Pat No. 5,706,830) a new type of closed circuit perfluorocarbon (PFC) liquid ventilator with enhanced capabilities for gas exchange and exudates clearance from the lungs. This system has potential application to rescue of patients in acute respiratory failure and treatment of cystic fibrosis. ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation

    SBC: REBISCAN, Inc.            Topic: N

    Project Summary/Abstract !Amblyopia is vision loss caused by neglect of a structurally normal eye due to strabismus, asymmetric refraction (anisometropia), or deprivation. It is irreversible if not treated by age 7, but half of all patients in the U.S. are undetected and untreated until after it is too late, making it the leading cause of preventable vision loss. Rebion (Rebiscan, Inc) has develop ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. A novel device for cervical insufficiency in pregnant women

    SBC: Cx Therapeutics, Inc            Topic: NICHD

    Abstract In normal pregnancy, the cervix remains closed until term and then dilates under the influence of uterine contractions. In cases of cervical insufficiency (CI), the cervix dilates in the second trimester in the absence of uterine contractions, which leads to a preterm birth. Infants born prematurely are at risk of lifelong morbidities including chronic lung disease, feeding difficulties, ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel, Field-Deployable, Biomimetic Narcotics Detector for the Identification of Fentanyl and Other Synthetic Opioids

    SBC: SEACOAST SCIENCE, INC.            Topic: NIDA

    AbstractThe alarming scope of the rapidly growing opioid epidemic has commanded the nation’s attention. The White House’s Council of Economic Advisers estimates that in 2015, the economic cost of the opioid crisis was over $504.0 billion (2.8% of GDP); and it is only expected to continue rising. Today, 1 in 5 fatalities amongst young adults is opioid related; with half a million fatal overdose ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. A novel role for Reelin therapeutics in inflammatory bowel disease

    SBC: REELIN THERAPEUTICS, INC.            Topic: 300

    Abstract Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely understood. Although specific genetic factors may increase risk, most IBD cannot be readily explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated. Once IBD is established, chronic inflammation is a central hallmark and also a major target for therapy. Both forms ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. A P. falciparum MSP1 p42/QS-21 malaria vaccine

    SBC: Agenus Inc.            Topic: N/A

    DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a disease which affects more than 300 million people each year and is fatal for 1.5 million. The overall objective of this STTR Phase I project is to produce a cGMP malaria vaccine consisting of the 42 kDa C-terminal polypeptide of P. falciparum merozoite surface protein-1 (MSP1.42) to be formulated with ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government